Archive

03_MemoNov 22, 2016
First Client Project Completed - Validation of MemoMAB Platform

 

 

06_Pieris

Oct 26, 2016
Pieris Pharmaceuticals to Receive GLP Tox Milestone Payment in Daiichi Sankyo Collaboration

 

 

01_EnOceanOct 11, 2016
EnOcean adds 2.4 GHz BLE modules to its product portfolio

 

 

05_ParatekOct 11, 2016
Paratek, U.S. Department of Defense Enter Research Agreement to Study Omadacycline Against Biodefense Pathogens

 

 

01_EnOceanSep 27, 2016
Intelligent Building expert becomes new President of EnOcean Inc.

 

 

06_PierisSep 26, 2016
Pieris Pharmaceuticals Presents Positive Data for Its Lead Bispecific Drug Candidate, PRS-343

 

 

02_NanotronSep 26, 2016
World-first Set of Productivity Tools for precise RTLS

 

 

Sep 17, 2016
Pharmaceuticals and medical technology will go hand in hand in future – DESITIN and cerbomed sign distribution agreement

 

 

03_MemoSep 14, 2016
Memo Therapeutics made it to the top 100 of Swiss startups for the second time in a row

 

 

sobera_NewsAug 16, 2016
Sobera Capital Takes Over Management of Private Equity Vehicles of Bavarian Savings Banks

 

 

05_ParatekAug 15, 2016
Paratek Initiates Phase 3 Study of Oral-only Omadacycline in ABSSSI

 

 

06_PierisAug 10, 2016
Pieris Pharmaceuticals Reports Financial Results and Provides Corporate Update
for the Second Quarter Ended June 30, 2016

 

02_ArravascJul 31, 2016
ArraVasc receives FDA 510(k) clearance for Pirouette 035 PTA catheter

 

 

lophiusJul 26, 2016
Lophius Biosciences Closed Financing Round of €4.25 Million to Expand Diagnostic
Developments into Tuberculosis and to Strengthen Marketing Activities

 

 

05_ParatekJun 27, 2016
Paratek Announces Closing of Common Stock Offering and Exercise in Full
of Underwriters’ Option to Purchase Additional Shares

 

 

02_NanotronJun 13, 2016
Nanotron starts shipping UWB Development Kit

 

 

03_MemoJun 15, 2016
First rabbit based client project started

 

 

06_PierisJun 8, 2016
Pieris Pharmaceuticals Announces Closing of $16.5 Million Private Placement

 

 

amicra

May 24, 2016
AMICRA to Provide Precision Die Attach System to Fabrinet in Silicon Valley

 

 

OneAccess Networks IP broadcast solutions for wireless networks France

May 17, 2016
Highlights assessment and implementation challenges operators face together with
prevailing options for fast and open network virtualization

 

 

03_Memo

May 15, 2016
Swiss government sponsored CTI/KTI R&D project

 

 

04_Neurotech

Apr 29, 2016
Neurotech Announces Renewed Focus on NT‐501 (CNTF)
Encapsulated Cell Therapy Clinical Programs

 

 

06_PierisMar 17, 2016
Pieris Pharmaceuticals Announces Presentation of In Vivo Preclinical Data
for Its Lead Bispecific Immuno-Oncology Drug Candidate, PRS-343

 

 

01_EnOcean

Mar 10, 2016
EnOcean Kinetic Power Conquers the World

 

 

03_Memo

Mar 1, 2016
Human antibodies in the treatment of Ebola

 

 

03_Memo

Feb 29, 2016
Proof of concept for rabbit based MemoMAB process

 

 

02_Nanotron

Feb 24, 2016
nanoLOX - The world-First Dual Mode Location Device

 

 

01_EnOcean

Feb 23, 2016
Element14 Unveils Two Self-Powered IoT Starter Kits
with EnOcean and IBM Technologies

 

 

05_ParatekJan 6, 2016
Paratek Accelerates Timing for Projected Reporting of Top-Line Data
for Omadacycline Phase 3 Skin Trial

 

 

02_Nanotron

Dec 21, 2015
Swarm Location Made Simple - Nanotron And Omnisense Cooperate on Easy-To-Use Location Solutions

 

 

03_ETH

Dec 11, 2015
Millenicom Sold to EWE Turkey

 

 

06_Pieris

Dec 8, 2015
Pieris Pharmaceuticals announces First Cancer Immunotherapy Collaboration

 

 

06_Pieris

Nov 30, 2015
Pieris Pharmaceuticals Achieves Payment Milestone in Sanofi Collaboration

 

 

02_Nanotron

Nov 30, 2015
Nanotron Expands Sales Channels in South Africa

 

 

06_PierisNov 19, 2015
Pieris Pharmaceuticals Collaborator Daiichi Sankyo Doses First Subject in a Phase 1 Clinical Study for Lead Partnered Anticalin Program

 

 

01_EnOcean

Nov 18, 2015
EnOcean and ASUS company AAEON partner to bring energy harvesting wireless technology to makers

 

 

05_ParatekNov 9, 2015
Paratek Initiates Omadacycline Phase 3 Clinical Study in Community Acquired Bacterial Pneumonia (CABP)

 

 

05_Paratek

Nov 4, 2015
Paratek Receives FDA Fast Track Designation for Omadacycline

 

 

02_Arravasc

Oct 28, 2015
ArraVasc receives CE Mark Approval for Pirouette 035 PTA Catheter

 

 

01_EnOcean

Oct 22, 2015
Battery-Free, Wireless Switching for all Platforms with EnOcean Click

 

 

02_Nanotron

Oct 9, 2015
Location-Aware Wireless Sensor Solutions for I4.0

 

 

02_Arravasc

Sep 30, 2015
ArraVasc Receives FDA 510(k) Clearance for Pirouette 018 PTA Catheter

 

 

06_Pieris

Sep 30, 2015
Positive Data Presented on Pieris Pharmaceuticals' Inhaled Asthma Program

 

 

06_Pieris

Sep 21, 2015
Pieris Pharmaceuticals Presents Positive Preclinical Data on Lead Bispecific Immuno-Oncology Program

 

 

05_Paratek

Sep 17, 2015
Paratek's Omadacycline Demonstrates Broad Spectrum Activity in Pathogens

 

 

06_Pieris

Sep 15, 2015
Pieris Pharmaceuticals' Collaborator Presents Promising Preclinical Data

 

 

04_Neurotech

Sep 2, 2015
Neurotech Announces First Patient Enrolled in Novel Anti VEGF Encapsulated Cell Therapy Study

 

 

06_Pieris

Jul 28, 2015
Pieris Pharmaceuticals Announces Closing of Over-Allotment Option in Public Offering of Common Stock

 

 

03_Memo

Jul 22, 2015
Memo Therapeutics Closes Series A Financing Round

 

 

06_Pieris

Jul 8, 2015
Pieris to Receive Seventh Milestone Payment From Daiichi Sankyo Collaboration to Develop Anticalin(R) Therapeutics

 

 

06_Pieris

Jul 7, 2015
Pieris Pharmaceuticals Closes Public Offering of Common Stock

 

 

06_Pieris

Jun 30, 2015
Pieris Pharmaceuticals Prices Public Offering of Common Stock

 

 

05_Paratek

Jun 23, 2015
Paratek Doses First Patient in Phase 3 Clinical Trial of Omadacycline in Acute Skin and Skin Structure Infections

 

 

06_Pieris

Jun 10, 2015
Pieris Pharmaceuticals Completes Dosing of Healthy Volunteers in Phase I Clinical Trial for Anticalin Program in Anemia

 

 

06_Pieris

May 14, 2015
Pieris Pharmaceuticals Appoints Immuno-Oncology Expert

 

 

06_Pieris

May 12, 2015
Pieris Pharmaceuticals Appoints Former Celgene and Sanofi Executive

 

 

03_OneAccess

May 5, 2015
Ellipse Projects Partners with OneAccess to Launch ONE1540 CPE Router in Thailand

 

 

06_Pieris

Mar 30, 2015
Pieris Pharmaceuticals and The University of Melbourne Receive
Research Grant to Advance Immunological Diseases Program

 

 

04_Neurotech

Mar 30, 2015
Neurotech Announces FDA Acceptance of IND

 



01_EnOcean

Mar 5, 2015
EnEnOcean Launches Complete Wireless LED Control System

 

 

01_EnOcean

Feb 17, 2015
EnEnOcean Launches Complete Wireless LED Control System

 

 

05_Paratek

Jan 6, 2015
Paratek to Receive $4 Million Payment From Actavis With Initiation of Phase 3 Trial of Sarecycline

 

 

Dec 23, 206_Pieris014
Pieris Pharmaceuticals, Inc completes private placement, raises $13.6M

 

 

sobera_News

Dec 18, 2014
Sobera Capital's portfolio company Pieris goes public

 

 

06_Pieris

Dec 18, 2014
Pieris Pharmaceuticals, Inc goes public, raises $ 12.2 million

 

 

06_Pieris

Dec 11, 2014
Pieris initiates phase I clinical trial for Anticalin® to treat Anemia

 

 

06_Pieris

Dec 8, 2014
Pieris achieves GLP tox milestone payment in Daiichi Sankyo collaboration
to develop Anticalin® therapeutics

 

 

05_Paratek

Dec 3, 2014
Paratek Pharmaceuticals announces appointment of Douglas Pagán as
Chief Financial Officer

 

 

06_Pieris

Dec 1, 2014
Pieris achieves second preclinical milestone in Sanofi collaboration

 

 

06_Pieris

Nov 12, 2014
Pieris appoints Michael Richman as supervisory board member

 

 

05_Paratek

Nov 4, 2014
Paratek Pharmaceuticals strengthens management team

 

 

03_OneAccess

Nov 3, 2014
Lime Link selects OneAccess Networks for their satellite VPN services

 

 

05_Paratek

Oct 30, 2014
Paratek Pharmaceuticals completes merger with Transcept Pharmaceuticals

 

 

03_OneAccess

Oct 9, 2014
OneAccess and Axiros Partner to increase agility of telco operators via Managed Network Service Delivery Platform

 

 

03_OneAccess

Oct 2, 2014
OneAccess Networks and SYNNEX Corporation enter into distribution agreement

 

 

01_EnOcean

Sep 22, 2014
Start-up expert becomes new CEO of EnOcean

 

 

03_OneAccess

Sep 22, 2014
OneAccess launches LTE enabled multi-service access router platform

 

 

sobera_News

Jul 3, 2014
Sobera Capital exits AnalytiCon

 

 

01_Analyticon

Jul 3, 2014
BRAIN in partnership with AnalytiCon Discovery

 

 

05_Paratek

Jul 1, 2014
Transcept Pharmaceuticals and Paratek Pharmaceuticals Sign Merger Agreement

 

 

05_Paratek

Jul 1, 2014
Paratek appoints Michael Bigham as Chairman and CEO and promotes Evan Loh to President and CMO

 

 

06_Pieris

Jun 23, 2014
Pieris achieves milestone payment in Daiichi Sankyo collaboration to develop Anticalin therapeutics

 

 

13_Scaleochip

Jun 17, 2014
Scaleo chip and IFP Energies nouvelles unveil OLEA in a plug-in hybrid car

 

 

01_EnOcean

May 28, 2014
Energy harvesting wireless product portfolio dedicated for China

 

 

03_OneAccess

May 19, 2014
Tokheim selects OneAccess to optimize business-critical international network

 

 

01_EnOcean

Apr 15, 2014
EnOcean introduces batteryless wireless solutions to the Japanese market

 

 

04_NeurotechApr 11, 2014
Quinton oswald appointed Chief executive officer of Neurotech Pharmaceuticals

 

 

01_EnOcean

Mar 31, 2014
EnOcean self-powers 2.4 GHz radio with kinetic energy

 

 

13_Scaleochip

Mar 10, 2014
Scaleo chip announces OLEA samples availability

 

 

sobera_News

Feb 19, 2014
Sobera Capital's portfolio company ACT Biotech sells oncology assets to Eddingpharm for up to $95 million

 

 

06_Pieris

Feb 10, 2014
Pieris achieves preclinical milestone payment in Sanofi collaboration

 

 

06_Pieris

Jan 13, 2014
Pieris achieves fourth milestone payment in Daiichi Sankyo collaboration to develop Anticalin therapeutics

 

 

01_EnOcean

Jan 8, 2014
NXP and EnOcean use NFC to simplify energy harvesting wireless in the smart home

 

 

01_ACTBJan 8, 2014
Eddingpharm acquired global rights to oncology assets, including Telatinib, from ACT Biotech